PARP

poly ADP ribose polymerase

PARP is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death. The PARP family comprises 17 members. They have all very different structures and functions in the cell. PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2 (PARP-5a or TNKS, and PARP-5b or TNKS2) have a confirmed PARP activity. Others include PARP3, PARP6, TIPARP (or PARP7), PARP8, PARP9, PARP10, PARP11, PARP12, PARP14, PARP15, and PARP16. PARP is found in the cell's nucleus. The main role is to detect and signal single-strand DNA breaks (SSB) to the enzymatic machinery involved in the SSB repair.

(8R,9S)-Talazoparib

((8R,9S)-BMN-673; (8R,9S)-LT-673)

Cat. No.: HY-16106A

(8R,9S)-Talazoparib ((8R,9S)-BMN-673) is an enantiomer of Talazoparib. (8R,9S)-Talazoparib is an **PARP1** inhibitor, with an IC_{50} of 144 nM.



Purity: 98.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

1,5-Isoquinolinediol

Cat. No.: HY-W015422

1,5-Isoquinolinediol is a potent **PARP** inhibitor, with an IC_{50} of 0.18-0.37 μM. 1,5-Isoquinolinediol attenuates diabetes-induced NADPH oxidase-derived oxidative stress in retina.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

2-Methylquinazolin-4-ol

Cat. No.: HY-W051513

2-Methylquinazolin-4-ol is a potent competitive **poly(ADP-ribose) synthetase** inhibitor, with a K_i of 1.1 μM. 2-Methylquinazolin-4-ol mammalian **aspartate transcarbamylase (ATCase)** inhibitor, with 0.20 mM.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Aminobenzamide

(PARP-IN-1)

Cat. No.: HY-12022

3-Aminobenzamide (PARP-IN-1) is a potent inhibitor of **PARP** with IC_{50} of appr
50 nM in CHO cells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.



Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 200 mg, 500 mg

3-Methoxybenzamide

(3-MBA)

Cat. No.: HY-121497

3-Methoxybenzamide (3-MBA), an inhibitor of **ADP-ribosyltransferase (ADPRTs)** and **PARP**, inhibits cell division in Bacillus subtilis, leading to filamentation and eventually lysis of cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4'-Methoxychalcone

Cat. No.: HY-128400

4'-Methoxychalcone regulates adipocyte differentiation through **PPARγ** activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

5,7-Dihydroxychromone

Cat. No.: HY-N1970

5,7-Dihydroxychromone, the extract of Cudrania tricuspidata, activates **Nrf2/ARE** signal and exerts neuroprotective effects against 6-hydroxydopamine (6-OHDA)-induced oxidative stress and **apoptosis**.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

5,7,4'-Trimethoxyflavone

Cat. No.: HY-N6818

5,7,4'-Trimethoxyflavone is isolated from Kaempferia parviflora (KP) that is a famous medicinal plant from Thailand.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

A-966492

Cat. No.: HY-10614

A-966492 is a novel and potent inhibitor of **PARP1** and < b>PARP2 with K_i of
1 nM and 1.5 nM, respectively.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AG14361

Cat. No.: HY-12032

AG14361 is a potent **PARP-1** inhibitor, with a K_i of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the IC_{50}s are 29 nM and 14 nM, respectively.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

AZ6102

Cat. No.: HY-12975

AZ6102 is a potent dual **TNKS1** and **TNKS2** inhibitor, with IC_{50}s of 3 nM and 1 nM, respectively, and alao has 100-fold selectivity against other PARP family enzymes, with IC_{50}s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PARP6, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZ9482

Cat. No.: HY-119653

AZ9482 is a triple **PARP1/2/6** inhibitor, with IC_{50} values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

AZD-2461

Cat. No.: HY-13536

AZD-2461 is a potent **PARP** inhibitor, with IC_{50}s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.



Purity: 98.21%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD5305

Cat. No.: HY-132167

AZD5305 is a potent, selective and oral active **PARP** inhibitor. AZD5305 is potent and efficacious in animal xenografts and PDX models.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Benzamide

(NSC-3114; Benzenecarboxamide; Phylamide)

Cat. No.: HY-Z0283

Benzamide inhibits **poly(ADP-ribose) polymerase (PARP)**.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

BGP-15

Cat. No.: HY-100828

BGP-15 is a **PARP** inhibitor, with an IC_{50} and a K_i of 120 and 57 μM, respectively.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BR102375

Cat. No.: HY-128344

BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (**PPAR γ**) full agonist for the treatment of type 2 diabetes, reveals EC_{50} value of 0.28 μM and A_{max} ratio of 98%.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRCA1-IN-1

Cat. No.: HY-100863

BRCA1-IN-1 is a novel small-molecule-like **BRCA1** inhibitor with IC_{50} and K_i of 0.53 μM and 0.71 μM, respecrively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRCA1-IN-2

Cat. No.: HY-100862

BRCA1-IN-2 (compound 15) is a cell-permeable protein-protein interaction (PPI) inhibitor for **BRCA1** with an IC_{50} of 0.31 μM and a K_d of 0.3 μM, which shows antitumor activities via the disruption of $BRCA1\ (BRCT)_2$/protein interactions.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

BYK204165

Cat. No.: HY-108632

BYK204165 is a potent and selective **PARP1** inhibitor. BYK204165 inhibits cell-free recombinant human PARP-1 (**hPARP-1**) with a pIC_{50} of 7.35 (pK_i=7.05), and murine PARP-2 (**mPARP-2**) with a pIC_{50} of 5.38, respectively. BYK204165 displays 100-fold selectivity for PARP-1.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Dehydrocorydaline

(13-Methylpalmatine) Cat. No.: HY-N0674

Dehydrocorydaline (13-Methylpalmatine) is an alkaloid isolated from traditional Chinese herb Corydalis yanhusuo W.T. Wang. Dehydrocorydaline regulates protein expression of **Bax**, **Bcl-2**; activates **caspase-7**, **caspase-8**, and inactivates **PARP**.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Dehydrocorydaline chloride

(13-Methylpalmatine chloride) Cat. No.: HY-N0674A

Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid isolated from traditional Chinese herb Corydalis yanhusuo W.T. Wang. Dehydrocorydaline regulates protein expression of **Bax**, **Bcl-2**; activates **caspase-7**, **caspase-8**, and inactivates **PARP**.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Dehydrocorydaline nitrate

(13-Methylpalmatine nitrate) Cat. No.: HY-N4238

Dehydrocorydaline nitrate (13-Methylpalmatine nitrate) is an alkaloid isolated from traditional Chinese herb Corydalis yanhusuo W.T. Wang. Dehydrocorydaline regulates protein expression of **Bax**, **Bcl-2**; activates **caspase-7**, **caspase-8**, and inactivates **PARP**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

DR2313

Cat. No.: HY-105692

DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of **poly(ADP-ribose) polymerase (PARP)**, with IC_{50}s of 0.20 μM and 0.24 μM for **PARP-1** and **PARP-2**, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E7449

Cat. No.: HY-12418

E7449 is a potent **PARP1** and **PARP2** inhibitor and also inhibits **TNKS1** and **TNKS2**, with IC_{50}s of 2.0, 1.0, 50 and 50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using ^{32}P-NAD$^+$ as substrate.



Purity: 97.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EB-47

Cat. No.: HY-15046

EB-47, a potent and selective **PARP-1/ARTD-1** inhibitor with an IC_{50} value of 45 nM, shows modest potency against ARTD5 with an IC_{50} value of 410 nM. EB-47 mimics the substrate NAD$^+$ and extends from the nicotinamide to the adenosine subsite.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

EB-47 dihydrochloride

Cat. No.: HY-108631

EB-47 dihydrochloride, a potent and selective **PARP-1/ARTD-1** inhibitor with an IC_{50} value of 45 nM, shows modest potency against ARTD5 with an IC_{50} value of 410 nM. EB-47 mimics the substrate NAD$^+$ and extends from the nicotinamide to the adenosine subsite.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fluorescein-NAD+

Cat. No.: HY-131009

Fluorescein-NAD+ is an alternative to radiolabeled NAD and a **substrate for ADP-ribosylation**. Fluorescein-NAD+ can be used in PARP assays by fluorescence microscopy. Extinction Coefficient: 262 nm.



Purity: >98%
Clinical Data: No Development Reported
Size: 81 μg

Fluzoparib

(SHR3162) Cat. No.: HY-114778

Fluzoparib (SHR3162) is a potent and orally active **PARP1** inhibitor (IC_{50}=1.46±0.72 nM, a cellfree enzymatic assay) with superior antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fucosterol

Cat. No.: HY-N4103

Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

G007-LK

Cat. No.: HY-12438

G007-LK is a potent and selective inhibitor of **TNKS1** and **TNKS2**, with IC_{50}s of 46 nM and 25 nM, respectively.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GeA-69

Cat. No.: HY-108708

GeA-69 is a selective, allosteric inhibitor of **poly-adenosine-diphosphate-ribose polymerase 14 (PARP14)** targeting macrodomain 2, with a K_d of 2.1 μM.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Iniparib

(BSI-201; NSC-746045; IND-71677)

Cat. No.: HY-12015

Iniparib (BSI-201) is an irreversible inhibitor of **PARP1**, used in the research of triple negative breast cancer.



Purity: 99.87%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

INO-1001

Cat. No.: HY-15045

INO-1001 is a potent and selective **poly (ADP-ribose) polymerase (PARP)** inhibitor. INO-1001 is a potent enhancer of radiation sensitivity and enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death.



Purity: 99.66%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

iRucaparib-AP6

Cat. No.: HY-130644

iRucaparib-AP6 is a highly efficient and specific **PARP1** degrader based on Rucaparib by using the PROTAC approach. iRucaparib-AP6, a non-trapping PARP1 degrader, blocks both the catalytic activity and scaffolding effects of PARP1.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

JW 55

Cat. No.: HY-13968

JW 55 is a potent and selective **β-catenin** signaling pathway inhibitor, which functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). JW 55 decreases auto-PARsylation of TNKS1/2 in vitro with IC_{50}s of 1.9 μM and 830 nM respectively.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

K-756

Cat. No.: HY-U00422

K-756 is a direct and selective **tankyrase** (**TNKS**) inhibitor, which inhibits the ADP-ribosylation activity of **TNKS1** and **TNKS2** with IC_{50}s of 31 and 36 nM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

ME0328

Cat. No.: HY-100225

ME0328 is a potent and selective **ARTD3/PARP3** inhibitor with an IC_{50} of 0.89±0.28 μM.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mefuparib hydrochloride

(MPH)

Cat. No.: HY-122661

Mefuparib hydrochloride (MPH) is an orally active, substrate-competitive and selective **PARP1/2** inhibitor with IC_{50}s of 3.2 nM and 1.9 nM, respectively. Mefuparib hydrochloride induces **apoptosis** and possesses prominent anticancer activity in vitro and in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MN-64

Cat. No.: HY-19351

MN-64 is a potent **tankyrase 1** inhibitor, with IC_{50}s of 6 nM, 72 nM, 19.1 μM, and 39.4 μM for **TNKS1**, TNKS2, ARTD1 and ARTD2, respectively.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Niraparib
(MK-4827) Cat. No.: HY-10619

Niraparib (MK-4827) is a highly potent and orally bioavailable **PARP1** and **PARP2** inhibitor with IC_{50}s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates **apoptosis** and shows anti-tumor activity.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Niraparib (R-enantiomer)
(MK 4827 (R-enantiomer)) Cat. No.: HY-10619D

Niraparib R-enantiomer (MK-4827 R-enantiomer) is an excellent **PARP1** inhibitor with IC_{50} of 2.4 nM.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Niraparib hydrochloride
(MK-4827 hydrochloride) Cat. No.: HY-10619A

Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable **PARP1** and **PARP2** inhibitor with IC_{50}s of 3.8 and 2.1 nM, respectively. Niraparib hydrochloride leads to inhibition of repair of DNA damage, activates **apoptosis** and shows anti-tumor activity.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Niraparib tosylate
(MK-4827 tosylate) Cat. No.: HY-10619B

Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable **PARP1** and **PARP2** inhibitor with an IC_{50} of 3.8 and 2.1 nM, respectively. Niraparib tosylate leads to inhibition of repair of DNA damage, activates **apoptosis** and shows anti-tumor activity.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NMS-P118
Cat. No.: HY-18954

NMS-P118 is a potent, orally available, and highly selective **PARP-1** Inhibitor for cancer therapy.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NMS-P515
Cat. No.: HY-128599

NMS-P515 is a potent, orally active and stereospecific **PARP-1** inhibitor, with a K_d of 16 nM and an IC_{50} of 27 nM (in Hela cells). Anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NU1025
Cat. No.: HY-15044

NU1025 is a potent **PARP** inhibitor with an IC_{50} of 400 nM and a K_i of 48 nM. NU1025 potentiates the cytotoxicity of ionizing radiation and anticancer drugs. NU1025 has anti-cancer and neuroprotective activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Nudifloramide
(2PY) Cat. No.: HY-113432

Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits **poly(ADP-ribose) polymerase (PARP-1)** activity in vitro.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

NVP-TNKS656
(TNKS656) Cat. No.: HY-13990

NVP-TNKS656 is a highly potent, selective, and orally active **TNKS2** inhibitor with IC_{50} of 6 nM, and is > 300 fold selectivity against **PARP1** and **PARP2**.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Olaparib
(AZD2281; KU0059436) Cat. No.: HY-10162

Olaparib (AZD2281; KU0059436) is a potent and orally active **PARP** inhibitor with IC_{50}s of 5 and 1 nM for **PARP1** and **PARP2**, respectively. Olaparib is an **autophagy** and **mitophagy** activator.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Olaparib D4

(AZD2281 D4; KU0059436 D4)

Cat. No.: HY-10162S2

Olaparib D4 (AZD2281 D4) is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active **PARP** inhibitor with **IC_{50}**s of 5 and 1 nM for **PARP1** and **PARP2**, respectively. Olaparib is an **autophagy** and **mitophagy** activator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Olaparib D5

(AZD2281 D5; KU0059436 D5)

Cat. No.: HY-10162S

Olaparib D5 (AZD2281 D5) is a deuterium labeled Olaparib. Olaparib is a potent and oral **PARP** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Olaparib D8

(AZD2281 D8; KU0059436 D8)

Cat. No.: HY-10162S1

Olaparib D8 (AZD2281 D8) is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active **PARP** inhibitor with **IC_{50}**s of 5 and 1 nM for **PARP1** and **PARP2**, respectively. Olaparib is an **autophagy** and **mitophagy** activator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oroxin A

Cat. No.: HY-N2025

Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE), activates peroxisome proliferator-activated receptor γ (**PPARγ**) by docking into the PPARγ protein ligand-binding domain.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

OUL35

(NSC39047)

Cat. No.: HY-123512

OUL35 (NSC39047) is a potent and selective inhibitor of **ARTD10 (PARP-10)**, with an **IC_{50}** of 329 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pamiparib

(BGB-290)

Cat. No.: HY-104044

Pamiparib (BGB-290) is an orally active, potent, highly selective **PARP** inhibitor, with **IC_{50}** values of 0.9 nM and 0.5 nM for **PARP1** and **PARP2**, respectively.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Paris saponin VII

(Chonglou Saponin VII)

Cat. No.: HY-N3584

Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii Maxim. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with **Akt/MAPK** and the inhibition of **P-gp**.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PARP-2-IN-1

Cat. No.: HY-102035

PARP-2-IN-1 is a potent and selective **PARP-2** inhibitor with an **IC_{50}** of 11.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP/PI3K-IN-1

Cat. No.: HY-133124

PARP/PI3K-IN-1 (compound 15) is a potent **PARP/PI3K** inhibitor with **pIC_{50}** values of 8.22, 8.44, 8.25, 6.54, 8.13, 6.08 for PARP-1, PARP-2, PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively. PARP/PI3K-IN-1 is a highly effective anticancer compound targeted against a wide range of oncologic diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP14 inhibitor H10

Cat. No.: HY-117889

PARP14 inhibitor H10, compound H 10, is a selective inhibitor against **PARP14** (**IC_{50}**=490 nM), over other PARPs (≈24 fold over PARP1). PARP14 inhibitor H10 induces caspase-3/7-mediated cell **apoptosis**.



Purity: 98.16%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

PJ34

Cat. No.: HY-13688A

PJ34 is a potent specific inhibitor of **PARPI/2** with IC_{50} of 110 nM and 86 nM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PJ34 hydrochloride

Cat. No.: HY-13688

PJ34 hydrochloride is an inhibitor of **PARP1/2** with IC_{50} of 110 nM and 86 nM, respectively.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

PROTAC PARP1 degrader

Cat. No.: HY-114324

PROTAC PARP1 degrader is a **PARP1** degrader based on the **PROTAC** technology. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC_{50} of 6.12 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RBN-2397

Cat. No.: HY-136174

RBN-2397 is a potent, accross species and orally active NAD^+ competitive inhibitor of **PARP7** (IC_{50}<3 nM). RBN-2397 selectively binds to PARP7 (K_d=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RBN012759

Cat. No.: HY-136979

RBN012759 is a potent, selective and orally active inhibitor of **PARP14**, with an IC_{50} of <3 nM. RBN012759 displays 300-fold selectivity over the monoPARPs and 1000-fold selectivity over the polyPARPs.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RK-287107

Cat. No.: HY-123892

RK-287107 is a potent and specific **tankyrase** inhibitor with IC_{50}s of 14.3 and 10.6 nM for **tankyrase-1** and **tankyrase-2**, respectively. RK-287107 blocks colorectal cancer cell growth.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rucaparib

(AG014699; PF-01367338)

Cat. No.: HY-10617A

Rucaparib (AG014699) is an orally active and potent inhibitor of **PARP** with K_i of 1.4 nM for PARP1 in a cell-free assay. Rucaparib shows binding affinity to eight other PARP domains.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Rucaparib Camsylate

Cat. No.: HY-102003

Rucaparib Camsylate is an inhibitor of **PARP** with a K_i of 1.4 nM for PARP1. Rucaparib Camsylate also shows binding affinity to eight other PARP domains.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rucaparib phosphate

(AG-014699 phosphate; PF-01367338 phosphate)

Cat. No.: HY-10617

Rucaparib phosphate (AG-014699 phosphate) is an orally active and potent **PARP** inhibitor, with a K_i of 1.4 nM for PARP1 in cell-free assay. Rucaparib phosphate shows binding affinity to eight other PARP domains.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Senaparib

(IMP4297)

Cat. No.: HY-137450

Senaparib (IMP4297) is a highly potent, selective and orally active **PARP1/2** inhibitor. Senaparib (IMP4297) exhibits strong antitumor activity in animal models.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Talazoparib

(BMN-673; LT-673) Cat. No.: HY-16106

Talazoparib (BMN-673) is a highly potent, orally active **PARP1/2** inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Talazoparib tosylate

(BMN 673ts) Cat. No.: HY-108413

Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available **PARP1/2** inhibitor with an IC_{50} of 0.57 nM for PARP1.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tankyrase-IN-2

Cat. No.: HY-126248

Tankyrase-IN-2 (compound 5k) is a potent, selective, and orally active **tankyrase** inhibitor (IC_{50}s of 10, 7, and 710 nM for TNKS1, TNKS2 as well as PARP1, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UPF 1069

Cat. No.: HY-14478

UPF 1069 is a **PARP** inhibitor, with IC_{50}s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Veliparib

(ABT-888) Cat. No.: HY-10129

Veliparib (ABT-888) is a potent **PARP** inhibitor, inhibiting **PARP1** and **PARP2** with K_is of 5.2 and 2.9 nM, respectively.



Purity: 99.78%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Veliparib dihydrochloride

(ABT-888 dihydrochloride) Cat. No.: HY-10130

Veliparib (dihydrochloride) is a potent inhibitor of **PARP1** a nd **PARP2** with K_is of 5.2 nM and 2.9 nM in cell-free assays, respectively.



Purity: 99.96%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Verminoside

Cat. No.: HY-N1094

Verminoside is an iridoid isolated from Kigelia africana, exhibits anti-inflammatory and remarkable antioxidant activity with a radical-scavenging activity of 2.5 μg/mL. The genotoxicity of Verminoside on human lymphocytes is associated with elevated levels of **PARP-1** and **p53** proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WD2000-012547

Cat. No.: HY-U00223

WD2000-012547 is a selective poly(ADP-ribose)-polymerase (PARP-1) inhibitor with a pK_i of 8.221.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WIKI4

Cat. No.: HY-16910

WIKI4 is a potent **tankyrase** inhibitor with an IC_{50} of 26 nM for **TNKS2**. WIKI4 potently inhibits **Wnt/β-catenin** signaling and that its half-maximal response dose is 75 nM.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

XAV-939

Cat. No.: HY-15147

XAV-939 is a potent **tankyrase** inhibitor that targets **Wnt/β-catenin signaling**. XAV-939 stabilizes axin by inhibiting **tankyrase 1** and **tankyrase 2** (IC_{50}s of 5 and 2 nM, respectively), thereby stimulating β-catenin degradation.



Purity: 98.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg